MOVFOR is an oral experimental antiviral drug which contains Molnupiravir.
It exerts its antiviral action through introduction of copying errors during viral RNA replication.
As per the studies performed in covid-19 patients, Molnupiravir has shown to shorten the time to recovery in some people.
During this pandemic the Drug Controller General of India (DCGI) has granted an accelerated review and approval of Molnupiravir to meet the urgent medical need for the treatment of COVID-19 through restricted medical use.
MOVFOR can be used easily in Home quarantine Patients as well as Hospitalized cases.
Frequently Asked Questions
A list of questions and answers relating to a particular subject,
especially one giving basic information for users of a website.
Covid-19 disease is now known to each & everyone. The impact that it has created in terms of loss of lives, sudden shutdown of economy, financial, emotional & physical losses will be engraved in History in coming times. COVID-19 is an infectious disease caused by the novel coronavirus.
Multiple variants of the virus that causes COVID-19 have been documented globally during the ongoing pandemic.
Viruses constantly change and become more diverse. Scientists monitor these changes, including changes to the spikes on the surface of the virus. By carefully studying viruses, scientists can learn how changes to the virus might affect how it spreads and how sick people will get from it.
So far six notable Covid-19 variants are discovered globally:
B.1.617.2 (Delta)
First identified in India in December 2020. A mutated version, Delta plus variant is recently diagnosed in India.
B.1.1.7 (Alpha)
First detected in the United Kingdom near December 2020.
B.1.351 (Beta)
First detected in South Africa in December 2020.
P.1 (Gamma)
First identified in travelers from Brazil, who were tested during routine screening at an airport in Japan, in early January.
B.1.427 and B.1.429 (Epsilon)
First identified in California in February 2021.
B.1.1.529 (Omicron)
First identified in South Africa in November 2021
These variants seem to spread more easily and quickly than other variants, which may lead to more cases of COVID-19. An increase in the number of cases will put more strain on healthcare resources, leading to more hospitalizations, and potentially more deaths.
So far, studies suggest that the current authorized vaccines work on the circulating variants. Scientists will continue to study these and other variants.
Worldwide till now 18.1 crores of population has been affected with Covid 19, while India has reported 3.03 crores Covid cases till date since inception
People with COVID-19 have reported a wide range of symptoms ranging from mild symptoms to severe illness. Symptoms may appear 2-14 days after exposure to the virus. Anyone can have mild to severe symptoms. People with these symptoms may have COVID-19:
Fever or chills
Cough
Shortness of breath or difficulty breathing
Fatigue
Muscle or body aches
Headache
New loss of taste or smell
Sore throat
Congestion or runny nose
Nausea or vomiting
Diarrhea
This list does not include all possible symptoms it is based on newer rising variants. Older adults and people who have severe underlying medical conditions like heart, lung disease or diabetes seem to be at higher risk for developing more serious complications from COVID-19 illness.
Remdesivir
In severe Hospitalized cases
Favipiravir
In mild to moderate Hospitalized or non-Hospitalized cases
MOVFOR is an oral experimental antiviral drug which contains Molnupiravir. It exerts its antiviral action through introduction of copying errors during viral RNA replication.
As per the studies performed in covid-19 patients, Molnupiravir has shown to shorten the time to recovery in some people.
During this pandemic the Drug Controller General of India (DCGI) has granted an accelerated review and approval of Molnupiravir to meet the urgent medical need for the treatment of COVID-19 through restricted medical use.
MOVFOR can be used easily in Home quarantine Patients as well as Hospitalized cases with COVID-19 mild disease.
MOVFOR is to be taken orally in a dose of 800 mg (four 200 mg capsules) for 5 days.
The doctor may consider the days of treatment depending on Patient’s health condition. MOVFOR may help decrease the amount of the coronavirus in body. This may help the Patient recover faster.
The capsules should be swallowed whole with a sufficient amount of fluid (e.g., a glass of water). The capsules should not be opened, crushed or chewed.
Tell your healthcare provider about all of your medical conditions, including if you
Have any allergies
Have kidney or liver problems
Are pregnant or plan to become pregnant
Are breastfeeding or plan to breastfeed
Have any serious illnesses such as heart disease or diabetes
Have been taking any medications for any other illnesses
Are taking any medicines (prescription, over-the-counter, vitamins, or herbal products). Molnupiravir may affect the way other medicines work, and other medicines may affect how molnupiravir works.
Especially tell your healthcare provider if you are taking the medicines chloroquine phosphate or hydroxychloroquine sulfate.
Common side effects are diarrhea, nausea, dizziness and headache and uncommon or rare are vomiting, rash and hives.
There are no studies conducted in humans or animals with the use of Molnupiravir.
No study is performed in pregnant women. Hence there is no data available. Doctor will need to evaluate the situation and decide whether to use MOVFOR in these patients.
MOVFOR should not be given during breast feeding and for 4 days after the last dose of molnupiravir.
Tell your healthcare provider right away if you have any side effect that bothers you or does not go away.
A formal statement testifying to someone's character and qualifications.
Akash (Mumbai)
I had to travel an official trip, when I came back I started feeling ill. I happen to experience sore throat, constant dry cough and slight fever. To clarify I gave RT PCR test and unfortunately got diagnosed as COVID positive. Based on my clinical conditions I was immediately prescribed with Molnupiravir for 5 days and asked to take them orally for 5 days every 12 hours without skipping any dosage. Gradually my health got better and after a while my health was getting better and the symptoms were fading away as the medicine was efficient in managing my situation.
Chaitanya (Delhi)
I was diagnosed with severe symptoms of CORONA. However, right action at the right time kept me out from Hospitalization. I was prescribed with Molnupiravir after diagnosis of Corona before it was too late. The medicine has safety and tolerability profile. It is the first oral, direct-acting antiviral medicine highly effective at reducing SARS-CoV-2 infectious virus and viral RNA.
Brinda (Bangalore)
I was diagnosed as COVID positive with heavy cough as a symptom. My doctor prescribed Molnupiravir as soon as it was diagnosed and magically the disease was controlled and my cough was decreasing gradually.
Advika (Bangalore)
I was diagnosed as COVID positive with heavy symptoms of cough, cold, and irritation in the throat. The doctor prescribed Molnupiravir based on my clinical conditions. It was a wonder to see that I was getting better and gradually relieved from all my symptoms.
Disclaimer: The content mentioned in this website is based on the published literature and is for informational purposes only.
Hetero Healthcare makes every effort to present accurate and reliable information, but does not warrant, or assume any legal liability or responsibility for,
the accuracy or completeness of any information provided. The product prescribing information complies with drug approval for use in Indian and may not reflect
regulatory approvals of other countries. The patient information is not intended to substitute professional advice and services of a qualified healthcare
professional. Any advice regarding the management of the medical condition is totally in the discreet of the physician’s knowledge and expertise.
